BFS
SYRE icon

Bare Financial Services’s Spyre Therapeutics SYRE Stock Holding History

Bare Financial Services’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.42K Hold
16
– – ﹤0.01% 1240
2026
Q1 		$807 Buy
+16
New +$603 ﹤0.01% 1345

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Bare Financial Services's SYRE Position: Q2 2026 in Review

Bare Financial Services held its Spyre Therapeutics (SYRE) position steady in Q2 2026 at 16 shares worth $1.42K. The position accounts for ﹤0.01% of the portfolio, ranked #1240.

Bare Financial Services first reported a position in SYRE in Q1 2026 and has held it in 2 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Bare Financial Services held 16 shares of Spyre Therapeutics worth $1.42K as of Q2 2026.
  • Bare Financial Services left its Spyre Therapeutics share count unchanged in Q2 2026.
  • Spyre Therapeutics made up ﹤0.01% of Bare Financial Services's portfolio in Q2 2026, its #1240 holding.
  • Bare Financial Services first reported a position in Spyre Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Bare Financial Services's 13F filing for Q2 2026, filed 27 Jul 2026.